Keyphrases
Acute ST-segment Elevation Myocardial Infarction
13%
All-cause Mortality
18%
Beta-blockers
12%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Chronic Heart Failure
13%
Confidence Interval
34%
Coronary Artery Disease
32%
Dapagliflozin
9%
Desmosine
20%
Diabetes
14%
Dilated Cardiomyopathy
9%
Echocardiography
14%
Ejection Fraction
15%
Elastin
10%
Electronic Health Records
11%
Endothelial Dysfunction
12%
Exercise-based Cardiac Rehabilitation
11%
Hazard Ratio
14%
Heart Disease Diagnosis
15%
Heart Failure
85%
Heart Failure Hospitalization
10%
Heart Failure Treatment
9%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Hypertension
14%
Incident Heart Failure
10%
Incremental Prognostic Value
9%
Inflammation
13%
Intramyocardial Hemorrhage
10%
Late Gadolinium Enhancement
13%
Left Ventricular Hypertrophy
17%
Left Ventricular Remodeling
20%
Major Adverse Cardiovascular Events
9%
Meta-analysis
20%
Metformin
26%
Odds Ratio
12%
Pathophysiology
13%
Patients with Diabetes
12%
Patients with Heart Failure
33%
Placebo
17%
Population Cohort Study
11%
Prognostic Significance
12%
Ruptured Abdominal Aortic Aneurysm (rAAA)
9%
Scotland
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
ST-elevation Myocardial Infarction (STEMI)
30%
Survivors
9%
Systematic Meta-analysis
9%
Tayside
10%
Type 2 Diabetes Mellitus (T2DM)
25%
Type 2 Diabetic Patients
10%
Medicine and Dentistry
Abdominal Aortic Aneurysm
8%
Aneurysm
8%
Aortic Stenosis
8%
Atrial Fibrillation
8%
Biological Marker
21%
Bleeding
8%
Cardiac Magnetic Resonance Imaging
23%
Cardiovascular Disease
28%
Cardiovascular Effect
6%
Cardiovascular System
15%
Cohort Analysis
17%
Congestive Heart Failure
99%
Coronary Angiography
6%
Coronary Artery Disease
27%
Desmosine
11%
Diabetes
16%
Diabetes Mellitus
6%
Dilated Cardiomyopathy
6%
Diseases
8%
Echocardiography
15%
Ejection Fraction
19%
Elastin
6%
Electronic Health Record
11%
Endothelial Dysfunction
9%
Gadolinium
13%
Glycon
20%
Hazard Ratio
9%
Heart Failure with Preserved Ejection Fraction
21%
Heart Failure with Reduced Ejection Fraction
16%
Heart Left Ventricle Ejection Fraction
7%
Heart Rehabilitation
8%
Heart Ventricle Remodeling
11%
Infarction
13%
Ischemic Heart Disease
10%
Kidney Function
6%
Left Ventricular Hypertrophy
14%
Loop Diuretic Agent
6%
Maturity Onset Diabetes of the Young
22%
Mendelian Randomization Analysis
7%
Meta-Analysis
13%
Myocardial Infarction
16%
Obstruction
7%
Odds Ratio
7%
Outpatient
6%
Pathophysiology
12%
Patient with Diabetes
9%
Patient with Type 2 Diabetes
6%
Placebo
13%
ST Segment Elevation Myocardial Infarction
30%
Systematic Review
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Aortic Aneurysm
9%
Acute Heart Infarction
5%
All Cause Mortality
8%
Aneurysm
8%
Atrial Fibrillation
6%
Beta Adrenergic Receptor Blocking Agent
6%
Biological Marker
18%
Bleeding
12%
Cardiovascular Disease
24%
Cardiovascular Risk
9%
Cohort Study
19%
Congestive Heart Failure
100%
Coronary Artery Disease
12%
Cotransporter
6%
Dapagliflozin
9%
Desmosine
14%
Diabetes Mellitus
9%
Diabetic Cardiomyopathy
5%
Diseases
10%
Diverticulitis
5%
Diverticulosis
5%
Elastin
9%
Endothelial Dysfunction
12%
Genetic Risk
5%
Heart Failure with Preserved Ejection Fraction
11%
Heart Failure with Reduced Ejection Fraction
18%
Heart Infarction
20%
Heart Left Ventricle Hypertrophy
12%
Heart Ventricle Remodeling
18%
Infarction
12%
Inflammation
15%
Ischemic Heart Disease
7%
Loop Diuretic Agent
9%
Metformin
20%
Nicorandil
5%
Non Insulin Dependent Diabetes Mellitus
18%
Obstruction
9%
Pathophysiology
12%
Placebo
20%
Randomized Controlled Trial
8%
Sodium Glucose Cotransporter 2 Inhibitor
5%
ST Segment Elevation Myocardial Infarction
32%